International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ... The lancet oncology 15 (12), e538-e548, 2014 | 4172 | 2014 |
BET bromodomain inhibition as a therapeutic strategy to target c-Myc JE Delmore, GC Issa, ME Lemieux, PB Rahl, J Shi, HM Jacobs, E Kastritis, ... Cell 146 (6), 904-917, 2011 | 2851 | 2011 |
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ... The lancet oncology 17 (8), e328-e346, 2016 | 1963 | 2016 |
Hematological findings and complications of COVID‐19 E Terpos, I Ntanasis‐Stathopoulos, I Elalamy, E Kastritis, TN Sergentanis, ... American journal of hematology 95 (7), 834-847, 2020 | 1770 | 2020 |
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors A Bamias, E Kastritis, C Bamia, LA Moulopoulos, I Melakopoulos, ... J Clin Oncol 23 (34), 8580-7, 2005 | 1542 | 2005 |
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes G Palladini, A Dispenzieri, MA Gertz, S Kumar, A Wechalekar, ... J Clin Oncol 30 (36), 4541-4549, 2012 | 832 | 2012 |
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid MA Dimopoulos, E Kastritis, C Bamia, I Melakopoulos, D Gika, M Roussou, ... Annals of Oncology 20 (1), 117-120, 2009 | 538 | 2009 |
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid MA Dimopoulos, E Kastritis, A Anagnostopoulos, I Melakopoulos, D Gika, ... haematologica 91 (7), 968-971, 2006 | 449 | 2006 |
Diagnosis of monoclonal gammopathy of renal significance F Bridoux, N Leung, CA Hutchison, G Touchard, S Sethi, JP Fermand, ... Kidney international 87 (4), 698-711, 2015 | 434 | 2015 |
Pathogenesis and treatment of renal failure in multiple myeloma MA Dimopoulos, E Kastritis, L Rosinol, J Bladé, H Ludwig Leukemia 22 (8), 1485-1493, 2008 | 426 | 2008 |
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis AD Wechalekar, SO Schonland, E Kastritis, JD Gillmore, MA Dimopoulos, ... Blood, The Journal of the American Society of Hematology 121 (17), 3420-3427, 2013 | 423 | 2013 |
Organ-specific manifestations of COVID-19 infection M Gavriatopoulou, E Korompoki, D Fotiou, I Ntanasis-Stathopoulos, ... Clinical and experimental medicine 20, 493-506, 2020 | 406 | 2020 |
International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 367 | 2016 |
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group N Leung, F Bridoux, V Batuman, A Chaidos, P Cockwell, VD D’Agati, ... Nature Reviews Nephrology 15 (1), 45-59, 2019 | 359 | 2019 |
European Myeloma Network guidelines for the management of multiple myeloma-related complications E Terpos, M Kleber, M Engelhardt, S Zweegman, F Gay, E Kastritis, ... haematologica 100 (10), 1254, 2015 | 356 | 2015 |
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis E Kastritis, AD Wechalekar, MA Dimopoulos, G Merlini, PN Hawkins, ... Journal of Clinical Oncology 28 (6), 1031-1037, 2010 | 338 | 2010 |
How I treat monoclonal gammopathy of renal significance (MGRS) JP Fermand, F Bridoux, RA Kyle, E Kastritis, BM Weiss, MA Cook, ... Blood, The Journal of the American Society of Hematology 122 (22), 3583-3590, 2013 | 327 | 2013 |
Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia MA Dimopoulos, A Tedeschi, J Trotman, R García-Sanz, D Macdonald, ... New England journal of medicine 378 (25), 2399-2410, 2018 | 281 | 2018 |
Response assessment in W aldenström macroglobulinaemia: update from the VI th I nternational W orkshop RG Owen, RA Kyle, MJ Stone, AC Rawstron, V Leblond, G Merlini, ... British journal of haematology 160 (2), 171-176, 2013 | 265 | 2013 |
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study SK Kumar, MA Dimopoulos, E Kastritis, E Terpos, H Nahi, H Goldschmidt, ... Leukemia 31 (11), 2443-2448, 2017 | 264 | 2017 |